These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported Terminated 2018-003436-74 A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-Centre, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Patien... 2019-08-14 due-trials
Ongoing 2020-005246-42 A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily ... not-yet-due
Trial is outside EEC 2021-001672-42 A Multicentre, Open Label, Balanced, Randomized, Single-Dose, Two-Stage, Two-Treatment, Two-Period, Two-Sequence, Two-Way, Cross-Over Study To Evaluate Comparative Bioavailability Of Temozolomide Powd... bad-data
Trial is outside EEC 2021-001768-95 AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWOSEQUENCE, SINGLE ORAL DOSE, CROSSOVER, COMPARATIVE BIOAVAILABILITY STUDY OF IMATINIB ORAL SOLUTION 800 MG/10 ML (AT A DOSE OF 05 ML) ... bad-data
Listed as ongoing, but also has a completion date 2021-001970-41 A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular Degen... 2024-10-25 bad-data
Trial is outside EEC 2021-004792-14 A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Compar... bad-data
Trial is outside EEC 2021-004897-77 A multicentric, open label, balanced, randomized, two-stage, two-treatment, two-period, two-sequence, crossover, multiple oral dose, comparative bioavailability study of cyclophosphamide powder for or... bad-data